Table 1.

Clinical, pathologic, and molecular features according to lymphocytic reactions to colorectal cancer

Clinical or molecular featureAll cases, n (%)Overall lymphocytic reaction score,*n (%)P
0-23-67-12
Total, n84354923064
Sex
    Male (HPFS)361 (43)240 (44)90 (39)31 (48)0.32
    Female (NHS)482 (57)309 (56)140 (61)33 (52)
Mean age (y) ± SD66.3 ± 8.365.8 ± 8.466.8 ± 8.169.1 ± 7.80.002
Body mass index (kg/m2)
    <30663 (84)425 (83)185 (85)53 (87)0.56
    ≥30 131 (16)90 (17)33 (15)8 (13)
Family history of colorectal cancer in first-degree relative(s)
    (−)637 (76)411 (75)178 (77)48 (75)0.75
    (+)206 (24)138 (25)52 (23)16 (25)
Year of diagnosis
    Prior to 1990148 (18)105 (19)37 (16)6 (9.4)0.20
    1990-1999598 (71)381 (69)164 (71)53 (83)
    2000-200297 (12)63 (11)29 (13)5 (7.8)
Tumor location
    Proximal (cecum to transverse)381 (45)206 (38)131 (57)44 (69)<0.0001
    Distal colon (splenic flexure to sigmoid)267 (32)185 (34)65 (28)17 (27)
    Rectum195 (23)158 (29)34 (15)3 (4.7)
AJCC tumor stage
    I187 (22)129 (24)44 (19)14 (22)0.002
    II242 (29)139 (25)76 (33)27 (42)
    III242 (29)150 (27)74 (32)18 (28)
    IV118 (14)95 (17)21 (9.1)2 (3.1)
    Unknown54 (6.4)36 (6.6)15 (6.5)3 (4.7)
No. of lymph nodes examined
    0-380 (12)62 (14)14 (7.3)4 (7.1)0.0007
    4-6105 (15)76 (17)24 (13)5 (8.9)
    7-12245 (36)162 (37)67 (35)16 (29)
    ≥13256 (37)138 (32)87 (45)31 (55)
No. of negative lymph nodes
    0-3131 (19)99 (23)27 (14)5 (8.9)<0.0001
    4-6125 (18)92 (21)25 (13)8 (14)
    7-12223 (33)138 (32)70 (36)15 (27)
    ≥13207 (30)109 (25)70 (36)28 (50)
Tumor grade
    Low755 (90)515 (95)200 (87)40 (63)<0.0001
    High82 (9.8)28 (5.2)30 (13)24 (37)
MSI
    MSI-low/MSS702 (85)503 (94)169 (74)30 (47)<0.0001
    MSI-high124 (15)31 (5.8)59 (26)34 (53)
CIMP
    CIMP-low/0685 (84)488 (93)165 (73)32 (50)<0.0001
    CIMP-high127 (16)34 (6.5)61 (27)32 (50)
Mean LINE-1 methylation (%) ± SD61.2 ± 9.460.4 ± 9.562.3 ± 8.663.8 ± 10.70.001
BRAF mutation
    (−)699 (86)479 (91)178 (81)42 (68)<0.0001
    (+)112 (14)49 (9.3)43 (19)20 (32)
KRAS mutation
    (−)528 (63)346 (64)135 (59)47 (73)0.11
    (+)304 (37)195 (36)92 (41)17 (27)
p53 expression
    (−)471 (57)271 (50)150 (66)50 (78)<0.0001
    (+)358 (43)267 (50)77 (34)14 (22)
COX-2 expression
    (−)136 (16)74 (14)50 (22)12 (19)0.015
    (+)701 (84)470 (86)179 (78)52 (81)

NOTE: Percentages in parentheses indicate the proportion of tumors with a specific clinical, pathologic, or molecular feature in all patients or patients with a specific category of lymphocytic reactions.

Abbreviations: HPFS, Health Professionals Follow-up Study; MSS, microsatellite stable; NHS, Nurses' Health Study; AJCC, American Joint Committee on Cancer.

  • *Overall lymphocytic reaction score is the sum of scores for Crohn's-like reaction (0-3), peritumoral reaction (0-3), intratumoral periglandular reaction (0-3), and TIL (0-3).